company background image
HMD

HeraMEDASX:HMD Stock Report

Market Cap

AU$37.2m

7D

10.5%

1Y

50.0%

Updated

21 Oct, 2021

Data

Company Financials
HMD fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

HMD Overview

HeraMED Limited, together with its subsidiaries, develops, manufactures, and sells foetal heart beat monitors and other pregnancy monitoring solutions for home use in Australia, Europe, and Israel.

Price History & Performance

Summary of all time highs, changes and price drops for HeraMED
Historical stock prices
Current Share PriceAU$0.21
52 Week HighAU$0.086
52 Week LowAU$0.30
Beta-0.42
1 Month Change2.44%
3 Month Change-4.55%
1 Year Change50.00%
3 Year Changen/a
5 Year Changen/a
Change since IPO16.67%

Recent News & Updates

Shareholder Returns

HMDAU Medical EquipmentAU Market
7D10.5%0.5%0.7%
1Y50.0%-8.2%21.4%

Return vs Industry: HMD exceeded the Australian Medical Equipment industry which returned -6.3% over the past year.

Return vs Market: HMD exceeded the Australian Market which returned 21.1% over the past year.

Price Volatility

Is HMD's price volatile compared to industry and market?
HMD volatility
HMD Beta-0.42
Industry Beta0.57
Market Beta1

Stable Share Price: HMD is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: HMD's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2011n/aDavid Grobermanhttps://www.hera-med.com

HeraMED Limited, together with its subsidiaries, develops, manufactures, and sells foetal heart beat monitors and other pregnancy monitoring solutions for home use in Australia, Europe, and Israel. The company provides HeraBEAT, a fetal heart rate monitor principally for use by an expectant mother to monitor their fetus’ heartbeat. It is also involved in developing EchoBEAT, the next generation of its home-oriented pregnancy monitoring devices; and Orion, an artificial intelligence powered pregnancy monitoring system for pregnancy monitoring analysis.

HeraMED Fundamentals Summary

How do HeraMED's earnings and revenue compare to its market cap?
HMD fundamental statistics
Market CapUS$27.87m
Earnings (TTM)-US$3.75m
Revenue (TTM)US$24.58k

1.2kx

P/S Ratio

-7.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
HMD income statement (TTM)
RevenueUS$24.58k
Cost of RevenueUS$8.14k
Gross ProfitUS$16.43k
ExpensesUS$3.77m
Earnings-US$3.75m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.021
Gross Margin66.86%
Net Profit Margin-15,262.00%
Debt/Equity Ratio9.2%

How did HMD perform over the long term?

See historical performance and comparison

Valuation

Is HeraMED undervalued compared to its fair value and its price relative to the market?

13.81x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate HMD's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate HMD's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: HMD is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.

PE vs Market: HMD is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate HMD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: HMD is overvalued based on its PB Ratio (13.8x) compared to the AU Medical Equipment industry average (4.6x).


Future Growth

How is HeraMED forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

14.0%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as HeraMED has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has HeraMED performed over the past 5 years?

-19.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HMD is currently unprofitable.

Growing Profit Margin: HMD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: HMD is unprofitable, and losses have increased over the past 5 years at a rate of 19.5% per year.

Accelerating Growth: Unable to compare HMD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HMD is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).


Return on Equity

High ROE: HMD has a negative Return on Equity (-185.76%), as it is currently unprofitable.


Financial Health

How is HeraMED's financial position?


Financial Position Analysis

Short Term Liabilities: HMD's short term assets ($2.3M) exceed its short term liabilities ($562.9K).

Long Term Liabilities: HMD's short term assets ($2.3M) exceed its long term liabilities ($644.0K).


Debt to Equity History and Analysis

Debt Level: HMD's debt to equity ratio (9.2%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if HMD's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: HMD has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: HMD has less than a year of cash runway if free cash flow continues to reduce at historical rates of 20.4% each year


Dividend

What is HeraMED current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate HMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HMD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HMD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HMD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HMD's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

David Groberman

no data

Tenure

US$211,911

Compensation

Mr. David Groberman is a Co-Founder and Chief Executive Officer of HeraMED Limited and also has been its Executive Director since September 25, 2018. Mr. Groberman has been developing multi-disciplinary me...


CEO Compensation Analysis

Compensation vs Market: David's total compensation ($USD211.91K) is below average for companies of similar size in the Australian market ($USD303.55K).

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: HMD's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

Experienced Board: HMD's board of directors are considered experienced (3.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.1%.


Top Shareholders

Company Information

HeraMED Limited's employee growth, exchange listings and data sources


Key Information

  • Name: HeraMED Limited
  • Ticker: HMD
  • Exchange: ASX
  • Founded: 2011
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: AU$37.210m
  • Shares outstanding: 177.19m
  • Website: https://www.hera-med.com

Location

  • HeraMED Limited
  • 6 Meir Ariel Street
  • POB 8576
  • Netanya
  • 4059300
  • Israel

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/21 18:20
End of Day Share Price2021/10/21 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.